17 results
8-K
EX-99.1
HOWL
Werewolf Therapeutics Inc
11 May 23
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:05am
that mWTX-330 delivers IL-12 selectively to the tumor environment to inhibit tumor growth in mouse models. The preclinical data demonstrate that mWTX-330
S-3
EX-1.2
HOWL
Werewolf Therapeutics Inc
10 May 22
Shelf registration
5:02pm
or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata
10-K
u3hni7f
24 Mar 22
Annual report
7:08am
10-Q
bblbcr39ly7bf85r
10 Jun 21
Quarterly report
7:03am
8-K
EX-10.1
pf48uwjq9dly x4hg
2 Jun 21
Entry into a Material Definitive Agreement
5:15pm
424B4
gjeyozsyg145
30 Apr 21
Prospectus supplement with pricing info
5:30pm
S-1/A
036jfr
26 Apr 21
IPO registration (amended)
6:06am
S-1/A
EX-1.1
d2nvjgi
26 Apr 21
IPO registration (amended)
6:06am
S-1
y567n0
8 Apr 21
IPO registration
5:03pm
S-1
EX-10.9
9yhcm0mwy91
8 Apr 21
IPO registration
5:03pm
S-1
EX-10.14
zblccm9 ou72v1t
8 Apr 21
IPO registration
5:03pm
- Prev
- 1
- Next